Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.67 |
| ▸ | CCR3 | P51677 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17562354 | 0.90 | ACHE (0.58) | ACHECCR3ALDH1A1CXCR4 | |
| SCHEMBL22751978 | 0.90 | ACHE (0.58) | ACHECCR3ALDH1A1CXCR4 | |
| SCHEMBL4505448 | 0.87 | CCR3 (0.61) | ACHECCR3ALDH1A1CXCR4SIGMAR1 | |
| SCHEMBL27616228 | 0.87 | CCR3 (0.61) | ACHECCR3ALDH1A1CXCR4 | |
| SCHEMBL24307313 | 0.84 | HRH3 (0.50) | ACHECCR3ALDH1A1 | |
| SCHEMBL14102447 | 0.84 | CCR3 (0.61) | ACHECCR3ALDH1A1CXCR4 | |
| SCHEMBL19728167 | 0.84 | ACHE (0.69) | ACHECCR3 | |
| SCHEMBL24317322 | 0.83 | FUCA1 (0.51) | ACHECCR3SIGMAR1 | |
| SCHEMBL20214251 | 0.83 | CCR3 (0.59) | ACHECCR3ALDH1A1CXCR4 | |
| SCHEMBL8254766 | 0.82 | CHRNB2 (0.59) | ALDH1A1CXCR4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10301253-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3250552-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-9981972-B2 | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981972-B2 | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180009735-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | H. LUNDBECK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | H. LUNDBECK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| US-20160046590-A1 | SONIC HEDGEHOG MODULATORS | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-02-18 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | ACHE 2931/4885CCR3 1947/4885ALDH1A1 665/4885 |
| US-20180009735-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, HDAC1, DOT1L | ACHE 3792/4885CCR3 4420/4885ALDH1A1 272/4885 |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | ACHE 43/4885CCR3 4801/4885ALDH1A1 1197/4885 |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | HPN, BCHE, PRSS1 | ACHE 119/4885CCR3 1854/4885ALDH1A1 1289/4885 |
| US-10301253-B2 | Therapeutic compounds and uses thereof | KDM1B, HDAC1, DOT1L | ACHE 3792/4885CCR3 4420/4885ALDH1A1 272/4885 |
| US-20160046590-A1 | SONIC HEDGEHOG MODULATORS | SHH, GLI1, SMO | ACHE 4800/4885CCR3 4483/4885ALDH1A1 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.